Factor exposure
Growth tilted with a strong quality bias.
H143 Research Intelligence
Research before
conviction.
A systematic framework for separating narrative from durable compounding—combining growth, financial health, expectations and valuation.
Private mandateProprietary capital onlyNo external subscriptions
Our research methodology →
Personal track record
Since 2020, Hari Patel’s personal investment activity has generated significant capital appreciation through year-to-date, providing an experienced foundation for H143 Capital’s research discipline and long-term process. These individual results are separate from H143 Capital’s performance and are not indicative of future outcomes.
Portfolio intelligence
Growth × financial health
Lower healthFinancial healthHigher health
GrowthValue
Growth-ledBalancedValue-led
RBRKRubrik
01 / 13A−MetricAssessmentSignal
Directional H143 research signals—not live financial data or price targets. Refresh after filings and material guidance changes.
Portfolio insights
Evidence over narrative
Earnings revisions
Track estimate direction after every reported quarter.
Valuation discipline
Test the thesis across multiples, DCF and downside cases.
Investment strategy
Growth, disciplined by financial reality.
H143 seeks durable growth where balance-sheet strength, improving economics and a rational valuation create a credible path to long-term compounding.
Business quality
Competitive position, customer retention, pricing power and management execution.
Financial health
Liquidity, leverage, EBITDA quality, free cash flow and dilution discipline.
Expectations
Revenue and earnings revisions, guidance credibility and catalyst visibility.
Valuation
PEG, P/E, PVG composite, DCF, book value and EV/EBITDA where applicable.
Current mandate
Research-led portfolio.
Founder-funded positions for H143 Capital’s initial growth phase. Holdings, structures and assessments may change as prices and evidence change.
Core equities
Defined-risk optionsLong-duration and risk-defined exposure
Portfolio considerations
2026 YTD performance
Loading adjusted market returns…
Adjusted market performance from the final 2025 trading close. Updated automatically after market close. Data may be delayed.
Scoring methodology
A matrix designed to be challenged.
Each company is assessed on consistent evidence. Scores are qualitative research inputs—not forecasts—and should be refreshed after earnings, guidance changes or material company events.
Growth
Revenue runway, market expansion, backlog, retention and operating leverage.
Financial health
Cash, leverage, free cash flow, EBITDA quality, dilution and capital intensity.
Expectations
Consensus revisions, guidance, estimate dispersion and catalyst timing.
Valuation
PEG, P/E, PVG composite, DCF, book value per share and EV/EBITDA.
Data standard
Financial statements and company guidance should come from the latest issuer filings and earnings materials. Analyst expectations and valuation inputs should be timestamped and sourced before public display. Biotech and pre-profit companies require pipeline-adjusted measures because conventional P/E or EBITDA may not be meaningful.
Research journal
Ideas in progress.
Portfolio observations, watchlist research and long-term perspectives—organized in a dedicated research journal.
PORTFOLIO NOTE 01 · NASDAQ: FLY
Firefly Aerospace
Contract momentum, lunar execution and the risks embedded in an ambitious space platform.
Read portfolio note →WATCHLIST BRIEF 01 · NYSE: ROLRollins, Inc.
Durable essential-services compounder under active review after a material valuation reset.
Read complete brief →INVESTMENT PERSPECTIVEMarket observations
Long-term perspectives on valuation, cycles and business quality.
Open observations →